Cadrenal Therapeutics retains Tungsten Advisors for strategic review
- Cadrenal Therapeutics initiated a formal strategic process to evaluate strategic partnerships, asset sales, and business combinations.
- Following the strategic advisor retainment announcement, the company's share price traded lower at $10.85.
- The company expects the strategic evaluation to leverage recent FDA alignment on its Phase 3 development pathway for CAD-1005.
Cadrenal Therapeutics (NASDAQ:CVKD) initiated a formal strategic review process and retained Tungsten Advisors as its exclusive financial advisor.
The strategic initiative aims to evaluate potential asset sales, commercialization partnerships, licensing deals, and broader business combinations.
The comprehensive evaluation covers its portfolio assets, including CAD-1005, tecarfarin, frunexian, and its second-generation CAD-2000 platform.
The company stated that the strategic process follows incoming interest from prospective partners and recent alignment with the FDA.
The strategic evaluation specifically builds upon ongoing partnering discussions surrounding the Phase 3 clinical development pathway for CAD-1005.
The company retains Tungsten Advisors to explore options that maximize shareholder value across its 12-LOX platform.
Frequently asked questions
More from United States
PACCAR reports stronger third-quarter results with revenue up 19%
Provident Financial net income falls 28% to $1.57 million
Aclaris reports ATI-052 Phase 1b results in two conditions
Armstrong World posts $475.8 million Q3 revenue amid strong growth
Centene reports $45.1 billion Q3 revenue and raises 2026 EPS guidance
Polaris raises 2026 earnings outlook after sales rise 10.9%
